drugset

drugset / Trial / NCT06203275

The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

NCT06203275 ↗

Phase 3 Unknown 44 enrolled aya ramadan ashmawy sarhan

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to investigate the effect of GRK2 inhibitor paroxetine on insulin resistance in patients with type 2 diabetes mellitus.

Timeline

Start: 2024-01
Primary completion: 2025-01
Completion: 2026-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Paroxetine	Small molecule	12.5 mg	—

Indications